Dynasore: Noncompetitive Dynamin GTPase Inhibitor for Endocytosis Research

Executive Summary: Dynasore is a cell-permeable, noncompetitive inhibitor of the dynamin GTPase family, exhibiting an IC₅₀ of 15 µM under standard in vitro conditions (APExBIO). It blocks dynamin-dependent endocytosis in multiple cell types, such as HL-1 cardiomyocytes and neurons, by inhibiting GTP hydrolysis required for vesicle scission (Wang et al., 2018). Dynasore reversibly inhibits transferrin uptake and synaptic vesicle endocytosis, providing a robust tool for dissecting vesicle trafficking and signaling pathways. The compound is insoluble in water but highly soluble in DMSO at concentrations ≥16.12 mg/mL, and should be stored at -20°C (APExBIO). Recent benchmarks confirm its efficacy in viral entry inhibition and mechanistic endocytosis studies (Wang et al., 2018).

Biological Rationale

Dynamin is a large GTPase involved in membrane fission during clathrin-mediated endocytosis, vesicle trafficking, and synaptic vesicle recycling. The GTPase activity of dynamin is essential for the scission of clathrin-coated vesicles from the plasma membrane (Wang et al., 2018). Dysregulation of dynamin-dependent processes is implicated in cancer, neurodegenerative diseases, and viral infection pathways. Pharmacological inhibition of dynamin enables precise dissection of endocytic pathways, making dynamin inhibitors crucial for basic and translational research in cell biology, oncology, and infectious diseases (Dynasore and the Future of Endocytosis Research). Unlike genetic knockdown, small molecule inhibitors such as Dynasore provide rapid, reversible, and concentration-dependent modulation of endocytosis.

Mechanism of Action of Dynasore

Dynasore is a noncompetitive inhibitor of dynamin GTPase activity. It targets human dynamin1, dynamin2, and Drp1, inhibiting their GTP hydrolysis without competing with GTP binding (Dynasore: Noncompetitive Dynamin GTPase Inhibitor for End...). The IC₅₀ for dynamin GTPase inhibition is 15 µM under assay conditions at 37°C in buffer pH 7.4 (APExBIO). Dynasore blocks scission of endocytic vesicles, leading to the accumulation of clathrin-coated pits at the plasma membrane. In living cells, this manifests as rapid and reversible inhibition of transferrin and synaptic vesicle uptake. Its effects are reversible upon washout, enabling temporal control over dynamin activity. Unlike competitive inhibitors, Dynasore does not interfere with GTP binding but directly impairs the catalytic hydrolysis of GTP by dynamin proteins. This selectivity allows researchers to dissect dynamin-dependent from dynamin-independent endocytic processes in cellular models (Dynasore: The Go-To Dynamin GTPase Inhibitor for Endocyto...).

Evidence & Benchmarks

• Dynasore at 80 µM significantly inhibits clathrin-mediated endocytosis of grass carp reovirus (GCRV104) in CIK (kidney) cells, reducing viral entry and replication (Wang et al., 2018, DOI).
• In HL-1 cardiomyocytes and neurons, 80 µM Dynasore reversibly blocks transferrin uptake and synaptic vesicle endocytosis, confirming its robust activity across cell types (APExBIO).
• Dynasore demonstrates rapid onset of action (within 2–5 minutes), with inhibition fully reversible after compound washout (Dynasore: Noncompetitive Dynamin GTPase Inhibitor for End...).
• In vitro, Dynasore has an IC₅₀ of 15 µM for dynamin1 GTPase, confirming high potency under cell-free assay conditions (APExBIO).
• Dynasore does not inhibit dynamin-independent endocytosis (e.g., caveolin or clathrin-independent pathways), enabling pathway-specific analyses (Wang et al., 2018).

This article extends 'Dynasore: Decoding Dynamin GTPase Pathways for Viral Entry' by providing updated quantitative benchmarks and clarifying solubility/handling protocols for diverse cell models.

Applications, Limits & Misconceptions

Primary Applications

• Endocytosis Research: Dissecting clathrin-mediated, dynamin-dependent vesicle trafficking.
• Viral Entry Studies: Blocking dynamin-dependent internalization of viruses (e.g., GCRV104) (DOI).
• Neuroscience: Studying synaptic vesicle recycling and neurotransmission dynamics.
• Cancer and Neurodegenerative Disease Models: Elucidating endocytic pathway involvement in disease (Dynasore: The Noncompetitive GTPase Inhibitor Redefining ...).
• Signal Transduction Pathway Study: Probing links between endocytosis and cell signaling.

Common Pitfalls or Misconceptions

• Dynasore is not effective for inhibiting caveolin-mediated or clathrin-independent endocytosis (DOI).
• It does not block endosomal acidification or microtubule-dependent trafficking, unlike compounds such as ammonium chloride or nocodazole.
• Dynasore is insoluble in water or ethanol; use DMSO for all stock and working solutions (APExBIO).
• Prolonged exposure or high concentrations (>100 µM) may cause off-target effects; always validate with proper controls.
• Dynasore is intended for research only, not for diagnostic or medical use.

Workflow Integration & Parameters

For optimal results, prepare Dynasore stock solutions in DMSO at ≥16.12 mg/mL. Warm at 37°C or sonicate to maximize solubility. Store aliquots at -20°C for several months to maintain compound integrity (APExBIO). Use working concentrations between 15–80 µM, adjusting based on cell type and assay duration. Apply compound 2–5 minutes before experimental induction to achieve rapid inhibition. Washout with DMSO-free buffer restores dynamin activity within minutes.

APExBIO supplies Dynasore as a solid for customizable solution preparation (the A1605 kit). For advanced troubleshooting, see 'Dynasore: The Go-To Dynamin GTPase Inhibitor for Endocytosis', which details workflow enhancements and alternative use-cases not covered here.

Conclusion & Outlook

Dynasore remains a gold-standard tool for dissecting dynamin-dependent endocytosis, vesicle trafficking, and signaling pathway crosstalk. Its rapid, reversible action and high selectivity enable rigorous studies in diverse models. Future advances may further refine its application scope and inform the design of next-generation GTPase inhibitors for translational research (Dynasore and the Future of Endocytosis Research).